Table 1.
Illustrates demographic characteristics, comorbidities, viral reactivation, and prognosis of the cases analyzed in this scoping review. Since not all case reports documented all information, we have created column reported to illustrate how many cases reported the variable of interest.
| Demographic Characteristics | |||
|---|---|---|---|
| Sex | |||
| Female | 31 (31/71, 43.66%) | ||
| Male | 40 (40/71, 56.34%) | ||
| Age (Years) | |||
| ≤18 | 4 (4/71, 5.63%) | ||
| 19–64 | 41 (41/71, 57.75%) | ||
| ≥65 | 26 (26/71, 36.62%) | ||
| Comorbidities | |||
| Reported | Positive | Negative | |
| CKD | 14 (14/71, 19.72%) | 10 (10/14, 71.43%) | 4 (4/14, 28.57%) |
| HTN | 27 (27/71, 38.02%) | 21 (21/27, 77.78%) | 6 (6/27, 22.22%) |
| Immunosuppression | 5 (5/71, 7.04%) | 3 (3/5, 60%) | 2 (2/5, 40%) |
| Viral Reactivation | |||
| Reported | Positive | Negative | |
| CMV | 43 (43/71, 60.56%) | 7 (7/43, 16.28%) | 36 (36/43, 83.72%) |
| HHV-6 | 43 (43/71, 60.56%) | 10 (10/43, 23.26%) | 33 (33/43, 76.74%) |
| EBV | 43 (43/71, 60.56%) | 9 (9/43, 20.93%) | 34 (34/43, 79.07%) |
| Prognoses | |||
| Reported | Positive | Negative | |
| Sequelae | 7 (7/71, 9.86%) | 6 (6/7, 85.71%) | 1 (1/7, 14.29%) |
| Reported | Discharged | Death | |
| Outcome | 69 (69/71, 97.18%) | 60 (60/69, 86.96%) | 9 (9/69, 13.04%) |
CKD = chronic kidney disease; CMV = cytomegalovirus; HHV-6 = human herpesvirus 6; EBV = Epstein–Barr virus.